心脏毒性
吡格列酮
下调和上调
兴奋剂
过氧化物酶体增殖物激活受体
罗格列酮
药理学
毒性
体内
炎症
敌手
化学
受体
阿霉素
细胞凋亡
医学
内分泌学
内科学
生物
化疗
生物化学
糖尿病
生物技术
2型糖尿病
基因
作者
Golnaz Pakravan,Maryam Peymani,Navid Abedpoor,Zahra Safaeinejad,Mehrdad Yadegari,Maryam Derakhshan,Mohammad Hossein Nasr‐Esfahani,Kamran Ghaedi
摘要
Abstract Doxorubicin (Dox) is an antitumor agent widely used in cancer therapy, with notable side effects of cardiac toxicity. Peroxisome proliferator‐activated receptor γ (PPARγ), is a transcriptional factor with antiapoptotic and anti‐inflammatory properties. Recently we indicated that cardiac toxicity of Dox was due to upregulation of miR‐130a and further suppressive effect on cardiac Pparγ in vitro. In this study, we extended our proposed hypothesis in vivo. To achieve this, pioglitazone (Pio) and GW9662 were used as the specific agonist and antagonist of Pparγ to treat Dox‐injected mice. Heart function, apoptosis, and inflammation in heart tissue were studied. Pretreatment of Dox‐injected mice with Pio resulted in elevated expression of Pparγ and suppression of miR‐130a. However, GW9662 pretreatment was unable to increase miR‐130a expression. Pio pretreatment led to partially cardiac toxicity limitation of Dox whereas GW9662 caused heart damage. Finally, our observation determined that activation of Pparγ was not adequate to reverse the Dox‐induced toxicity completely.
科研通智能强力驱动
Strongly Powered by AbleSci AI